Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Delivery
- Device
- HPV
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28544
License Grant
The Canadian Licensor granted the Licensee an exclusive, worldwide License to taribavirin, excluding the territory of Japan.
License Property
Taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. It is believed that taribavirin (TBV) may present an alternative therapy to ribavirin (RBV) for the treatment of hepatitis C by delivering similar efficacy to ribavirin but with significantly less anemia, which is the main treatment-limiting toxicity associated with ribavirin.
IPSCIO Record ID: 275810
License Grant
Licensors have filed suit and/or counterclaims against Licensee in Europe and the United States contending that Licensee intended commercialization of its ribavirin product would infringe one Licensors patents relating to ribavirin.
Licensee has filed suit, opposition proceedings and/or counterclaims against Licensors contending that one Licensors ribavirin patents are neither valid nor infringed by Licensees intended commercialization of ribavirin.
This agreement is to obviate the need for such contested proceedings in favor of one Licensor granting a non-exclusive license to Licensee under that one Licensors ribavirin patents.
Licensor grants to the Swiss Licensee a non-exclusive, non-transferable and non-sublicensable right and license under the Licensed Patents within the Field throughout the Territory to make, have made, use, sell and distribute Products.
License Property
Licensor is the owner of patents in various countries which contain claims relating to certain pharmaceutical uses of ribavirin, an oral antiviral product.
The patents are for Ribavirin Human Use, and, Th1/Th2 Patents relating to Specific Modulation of TH1/TH2 Cytokine Expression, and, Cytokine Related Treatments of Disease.
Product means any pharmaceutical product consisting of or containing the Licensed Compound which is promoted and sold for use in combination with PEG-IFN-alpha, including without limitation a Combined Product.
Licensed Compound means oral ribavirin, having the chemical formula 1-(beta)-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. For the avoidance of doubt, oral ribavirin does not include prodrugs of ribavirin such as viramidine.
Field of Use
Field means the use of the Licensed Compound in combination therapy with PEG-IFN-alpha for the treatment of chronic hepatitis C. Licensee has developed an antiviral product containing ribavirin.
IPSCIO Record ID: 223111
License Grant
The parties agreed to amend the Agreement to increase certain royalty payments to Licensor in exchange for Licensor relinquishing its rights and granting to Licensee exclusive rights to develop, distribute, market, use, make, have made and sell the Product alone or as part of a combination therapy for the treatment of chronic hepatitis C in the EU; and to modify certain other provisions of the Agreement in order to achieve consistency with the objective of this amendment granting Licensee exclusive rights to the Product in the Territory.
License Property
Product means any oral product containing as its sole active ingredient ribavirin and any Improvements thereto. The term Product also shall include any Pharmaceutical product for the treatment of chronic hepatitis C containing oral ribavirin in combination with another active ingredient; provided, however, that nothing in this Agreement shall be deemed to grant any rights or license to recombinant interferon alfa 2b.
Field of Use
This agreement pertains to the drug industry relating to the treatment of chronic hepatitis C.
IPSCIO Record ID: 1165
License Grant
The license agreement assigns to the Licensee, Viratek’s exclusive license from a University covering the aerosol device used to deliver ribavirin (Virazole(R)) to the lungs.
License Property
VIRAZOLE® is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to Respiratory Syncytial Virus (RSV). Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.
Field of Use
Ribavirin is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a), and other viral infections.
IPSCIO Record ID: 240608
License Grant
Licensor grants to Swiss Licensee and its Affiliates, and Licensee accepts on behalf of itself and its Affiliates, a non-exclusive, non-transferable and non-sublicensable right and license under the Licensed Patents within the Field throughout the Territory to make, have made, use, sell and distribute Products. Licensee has no right or license with respect to the Licensed Patents except as expressly granted in this Agreement.
License Property
Licensed Patents means rights under patents and patent applications in the Field, as well as corresponding certificates of invention or certificates of protection, substitutes, extensions, provisionals, supplementary protection certificates, renewals, continuations, continuations-in-part, divisions, patents of addition (re-examination or re-issue), in any country of the Territory, which are owned by, or licensed to, Licensor and/or its Affiliates as of the Effective Date or during the term of this Agreement which relate to the use of the Licensed Compound in the Field. In particular, Licensed Patents shall include (i) the Arbovirus Patents, (ii) the Th1/Th2 Patents and (iii) those other patents and patent applications listed.
USA Patent #6423695 – Cytokine Related Treatments of Disease
USA Patent #5767097 – Specific Modulation of TH1/TH2 Cytokine Expression
USA Patent #6063772 – Specific Modulation of TH1/TH2 Cytokine Expression
Product means any pharmaceutical product consisting of or containing the Licensed Compound which is promoted and sold for use in combination with PEG-IFN-alpha, including without limitation a Combined Product.
Licensed Compound means oral ribavirin, having the chemical formula 1-(beta)-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. For the avoidance of doubt, oral ribavirin does not include prodrugs of ribavirin such as viramidine.
Field of Use
Field means the use of the Licensed Compound in combination therapy with PEG-IFN-alpha for the treatment of chronic hepatitis C.
IPSCIO Record ID: 223110
License Grant
Licensor hereby grants to Swiss Licensee, as of the Effective Date, (a) the exclusive licenses, exclusive even with respect to Licensor, to make, have made, develop, use, sell and distribute Product for the treatment of chronic hepatitis C, in each country in the Territory during the Exclusive Period (1) under the Know-How and (2) at Licensees option, under either the Licensor Trademark or the Licensee Trademark, and (b) the non-exclusive license in and to the Know-How to enable Licensee to make, have made, develop, use, sell and distribute the Product for the treatment of chronic hepatitis C in the Territory during the License Period.
License Property
Licensor Trademark means Virazole and any and all variations thereof and/or substitute marks proposed, chosen, owned or controlled by Licensor or its Affiliates for use with the Product in the Territory.
Product means any oral product containing as its sole active ingredient ribavirin and any Improvements thereto. The term 'Product' also shall include any Pharmaceutical product for the treatment of chronic hepatitis C containing oral ribavirin in combination with another active ingredient; provided, however, that nothing in this Agreement shall be deemed to grant to Licensor any rights or license to recombinant interferon alfa 2b.
Field of Use
Field of use is for the treatment of chronic hepatitis C as a Therapy (Retreatment).
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and is spread through contact with blood from an infected person. Chronic hepatitis C can result in serious health problems like cirrhosis and liver cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
